<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Nine patients (median age, 58; range: 37-74) with relapsed de novo <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) (3), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> after prior <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (4), or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (2) were treated with 2-20 x 10(6) U/m2/day (1-10 mg/m2/day) of recombinant human interferon gamma (rIFN gamma; Biogen) on a 14-day continuous intravenous infusion schedule </plain></SENT>
<SENT sid="1" pm="."><plain>The two patients who received the initial dose of 20 x 10(6) U/m2/day (1.0 mg/m2/day) could only tolerate 6 days of therapy because of severe <z:e sem="disease" ids="C0235378,C0348754" disease_type="Disease or Syndrome;Injury or Poisoning" abbrv="">hepatotoxicity</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Two patients who received the revised starting dose of 10 x 10(6) U/m2/day also could not complete a full course of rIFN gamma due to <z:hpo ids='HP_0000083'>renal failure</z:hpo> in one case and pulmonary deterioration in the other </plain></SENT>
<SENT sid="3" pm="."><plain>A reversible dose-related rise in SGOT was seen in six patients </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients developed a severe <z:e sem="disease" ids="C1558931" disease_type="Disease or Syndrome" abbrv="">flu-like syndrome</z:e> characterized by <z:hpo ids='HP_0003326'>myalgias</z:hpo> and <z:hpo ids='HP_0001945'>fevers</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>These toxicities were not associated with detectable serum levels of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF) </plain></SENT>
<SENT sid="6" pm="."><plain>Although blasts from three of five assessable patients displayed increased expression of the Ia (HLA-DR) antigen, there were no hematological responses </plain></SENT>
<SENT sid="7" pm="."><plain>Steady-state rIFN gamma plasma levels in patients who tolerated a complete infusion were &lt; 40 U/ml, a concentration below that required to induce differentiation of myeloid leukemic cell lines in vitro </plain></SENT>
<SENT sid="8" pm="."><plain>We conclude that continuous infusions of rIFN gamma at doses as low as 2 x 10(6) U/m2/day are poorly tolerated in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; the maximum tolerated dose is approximately 2 x 10(6) U/m2/day </plain></SENT>
</text></document>